Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Announces First Patient Dosed in Trial to Determine PENNVAX®-GP’s Ability to Induce Remission of HIV Infection

PLYMOUTH MEETING, Pa., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the first participant has been dosed with PENNVAX®-GP in a randomized clinical...
August 07, 2018 16:05 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals Reports 2018 Second Quarter Financial Results

PLYMOUTH MEETING, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA...
August 06, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Partners with AIDS Malignancy Consortium to Advance Inovio’s HPV Therapy for High-Grade Anal Dysplasia in HIV-positive Patients

PLYMOUTH MEETING, Pa., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has entered into a partnership with the AIDS Malignancy Consortium (AMC) to...
July 24, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 7, 2018

PLYMOUTH MEETING, Pa., July 24, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2018 second...
June 27, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio’s MERS Vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study

PLYMOUTH MEETING, Pa., June 27, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced positive Phase 1 results of its collaborative vaccine study with INO-4700...
June 21, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor

PLYMOUTH MEETING, Pa., June 21, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has dosed its first patient as part of its Phase 1/2 immuno-oncology trial...
May 31, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio CEO to Speak on Viral Epidemic Preparedness Panel at BIO International Convention

PLYMOUTH MEETING, Pa., May 31, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, will address Inovio’s ability to respond...
May 24, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Boosts Leadership Focused on Partnership and Grant Funding By Appointing Two New VPs for Business Development and R&D

PLYMOUTH MEETING, Pa., May 24, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has bolstered its efforts to attract partnerships and collaborations and...
May 21, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV – The No. 1 Sexually Transmitted Disease

PLYMOUTH MEETING, Pa., May 21, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has commenced a Phase 2 clinical trial to evaluate the efficacy of VGX-3100...
May 17, 2018 08:00 ET | Source: Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer

PLYMOUTH MEETING, Pa., May 17, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a poster presentation of additional prostate cancer data (Abstract #229675) at the...